Semaglutide 4mg in the Wegovy titration: what to expect at this stage

Step 1: understanding where 4mg sits in the sequence

Wegovy's titration schedule exists for a specific reason: starting at a therapeutic dose would make side effects intolerable for most people. So the first several months of treatment are about graduated adjustment. The standard monthly steps run 0.25mg, 0.5mg, 1mg, 1.7mg, and then 2.4mg maintenance, each held for roughly four weeks before the next increase.

The 4mg dose is not an official step in that labelled sequence; it is most relevant in the context of the newer Wegovy 4mg format, which some patients encounter as part of their titration packaging or when the 7.2mg higher-dose pathway was introduced. Either way, around the twelve-week mark you are climbing toward doses where semaglutide's appetite-suppressing effect becomes meaningfully stronger. Your prescriber reviews your progress before each increase, at nume, that review happens before any repeat is dispatched.

If you are curious about what the phase 3 STEP trial evidence shows about outcomes across the full titration period, that page covers the clinical data in detail. The short version: the larger appetite reduction in trials was observed once patients reached and sustained the 2.4mg maintenance dose over 68 weeks.

Step 2: what is happening in your body at this stage

By the time most patients reach the 4mg-equivalent stage, the medicine has been active for a couple of months. Semaglutide binds GLP-1 receptors in the gut and brain, slowing how quickly your stomach empties and dampening hunger signals. At lower doses that effect is partial; as the dose increases, so does the strength of those signals.

Practically, people often notice they feel full faster, forget to finish meals, or find previously appealing foods less interesting. Those effects tend to deepen with each dose step. A smaller number of people notice that nausea (which may have been present earlier) flares again briefly after each increase before settling. That is a normal physiological response to a stronger dose, not a sign something has gone wrong.

The NHS medicines page for semaglutide lists the full side-effect profile with clear guidance on which symptoms warrant contacting a clinician. Worth bookmarking if you are mid-titration.

Step 3: managing the transition and knowing when to flag concerns

Most people move through the intermediate doses without significant problems. A few practical things help. Eating more slowly, choosing smaller portions of lower-fat foods, and staying well hydrated all reduce GI upset during a dose increase. Protein intake matters here, appetite falls, so getting enough protein per meal becomes an active effort rather than something that just happens.

There are symptoms that need prompt medical attention, not a wait-and-see approach. Severe, persistent stomach pain that spreads toward the back (with or without vomiting) should be assessed urgently, as it can indicate pancreatitis. The MHRA issued a Drug Safety Update in January 2026 specifically reminding prescribers and patients that acute pancreatitis, while uncommon, is a recognised risk with GLP-1 medicines. Gallbladder symptoms (sharp upper-right abdominal pain, particularly after eating) also warrant a call to your GP or 111.

For context on reaching and sustaining the 2.4mg maintenance dose, including what the evidence says about weight loss at that stage, that page goes into the trial data properly. It is the step most people are ultimately working toward.

Semaglutide 4mg and what it tells you about your next steps

How your body responds around this point in titration gives your prescriber useful information. If you have tolerated earlier doses well and your weight is tracking in the right direction, the plan is usually to continue. If side effects have been significant, the prescriber may recommend spending longer at the current dose before stepping up. That is not a failure, it is the schedule doing its job.

Private treatment through a regulated pharmacy means those reviews happen without the waiting-list pressures of NHS referral pathways. You can read about how different weight-loss treatment options compare in terms of eligibility and process on our treatment overview page. For a sense of typical private costs, the Wegovy price comparison page sets out the honest picture of what affects what you pay, consultation fees, dose, and what aftercare is included all vary by provider.

At this stage in treatment, the most useful thing is consistent clinical oversight. Our prescribers are available seven days a week for aftercare, not a contact form with a 48-hour turnaround, but a real response. If you are considering starting, or transferring from another provider, speak to our prescribers to check your suitability and talk through where you are in the process.